Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CRE Escherichia coli

Proceedings of the National Academy of Sciences of the United States of America
Thomas R. AuninsAnushree Chatterjee

Abstract

In recent years, the prevalence of carbapenem-resistant Enterobacteriaceae (CRE) has risen substantially, and the study of CRE resistance mechanisms has become increasingly important for antibiotic development. Although much research has focused on genomic resistance factors, relatively few studies have examined CRE pathogens through changes in gene expression. In this study, we examined the gene expression profile of a CRE Escherichia coli clinical isolate that is sensitive to meropenem but resistant to ertapenem to explore transcriptomic contributions to resistance and to identify gene knockdown targets for carbapenem potentiation. We sequenced total and short RNA to analyze the gene expression response to ertapenem or meropenem treatment and found significant expression changes in genes related to motility, maltodextrin metabolism, the formate hydrogenlyase complex, and the general stress response. To validate these findings, we used our laboratory's Facile Accelerated Specific Therapeutic (FAST) platform to create antisense peptide nucleic acids (PNAs), gene-specific molecules designed to inhibit protein translation. PNAs were designed to inhibit the pathways identified in our transcriptomic analysis, and each PNA was then ...Continue Reading

References

Feb 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·L Good, P E Nielsen
Jan 30, 1999·Antimicrobial Agents and Chemotherapy·T KöhlerJ C Pechere
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·D M Livermore
Apr 3, 2001·Nature Biotechnology·L GoodP E Nielsen
Sep 15, 2001·Antimicrobial Agents and Chemotherapy·D M LivermoreM Warner
Jan 5, 2002·Expert Opinion on Investigational Drugs·I Odenholt
May 9, 2003·Journal of Molecular Microbiology and Biotechnology·Karen Joy ShawBrian J Morrow
Aug 15, 2003·The Journal of Antimicrobial Chemotherapy·David M LivermoreGeoffrey M Scott
May 20, 2004·The Journal of Antimicrobial Chemotherapy·Milton L Hammond
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·George A JacobyNancy Chow
Mar 11, 2005·Expert Review of Anti-infective Therapy·George G ZhanelDaryl J Hoban
May 8, 2007·Emerging Infectious Diseases·Marie-Frédérique LartiguePatrice Nordmann
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Apr 29, 2008·Nucleic Acids Research·Mark JohnsonThomas L Madden
Sep 9, 2008·International Journal of Antimicrobial Agents·Jesús OteoJosé Campos
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Jan 30, 2010·Bioinformatics·Aaron R Quinlan, Ira M Hall
Oct 29, 2010·Genome Biology·Simon Anders, Wolfgang Huber
Nov 26, 2010·Nucleic Acids Research·Ingrid M KeselerPeter D Karp
Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil GuptaAlexander J Kallen
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Jan 13, 2012·Journal of Clinical Microbiology·Mette V LarsenOle Lund
Mar 6, 2012·Nature Methods·Ben Langmead, Steven L Salzberg
Apr 18, 2012·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Anton BankevichPavel A Pevzner
Feb 21, 2013·Bioinformatics·Alexey GurevichGlenn Tesler
May 11, 2013·International Journal of Medical Microbiology : IJMM·Chee-Hock HoeThean-Hock Tang
May 30, 2013·Nucleic Acids Research·Ryan McClureBrian Tjaden
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Sushim Kumar GuptaJean-Marc Rolain
Apr 4, 2014·Bioinformatics·Anthony M BolgerBjoern Usadel

❮ Previous
Next ❯

Citations

May 1, 2021·Biomedicines·Saumya JaniMarcelo E Tolmasky
Aug 28, 2021·International Journal of Molecular Sciences·Petra PusicUdo Bläsi
Nov 7, 2021·Communications Biology·Peter B OtoupalAnushree Chatterjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.